NecstGen and ProteoNic report development of improved viral vectors through the application of premium 2G UNic™ technology

Posted on by

LEIDEN, the Netherlands, Sept. 19, 2023 /PRNewswire/ — Necstgen, a non-profit CDMO and ProteoNic, a leading provider of premium vector technology and services for efficient production of biologics, announce the successful development of improved lentiviral (LV) vectors, driving higher…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.